In Vivo Correction of Murine Hereditary Tyrosinemia Type I by ϕC31 Integrase-Mediated Gene Delivery
Open Access
- 31 March 2005
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 11 (3) , 399-408
- https://doi.org/10.1016/j.ymthe.2004.11.001
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Construction of Transgenic Drosophila by Using the Site-Specific Integrase From Phage C31Genetics, 2004
- LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1Science, 2003
- Site-specific genomic integration produces therapeutic Factor IX levels in miceNature Biotechnology, 2002
- Stable Expression of the Alkaline Phosphatase Marker Gene by Neural Cells in Culture and after Transplantation into the CNS Using Cells Derived from a Transgenic RatExperimental Neurology, 2002
- Lentiviral Gene Transduction of KidneyHuman Gene Therapy, 2002
- Linear DNAs Concatemerize in Vivo and Result in Sustained Transgene Expression in Mouse LiverMolecular Therapy, 2001
- In Vivo Selection of Hepatocytes Transduced with Adeno-Associated Viral VectorsMolecular Therapy, 2000
- Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type INature Genetics, 1995
- p21 is a universal inhibitor of cyclin kinasesNature, 1993
- WAF1, a potential mediator of p53 tumor suppressionCell, 1993